Antinociceptive interactions of mu- and kappa-opioid agonists in the colorectal distension assay in rats

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 2, 2009, Pages 343-350

  Briggs, Shannon L ^b   Rech, Richard H ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b State of Michigan ^*  (United States)

Author keywords

CRD; Fentanyl; Mu and kappa opioids; Opioid antagonists; Spiradoline; Visceral pain

Indexed keywords

ANTINOCICEPTIVE AGENT; BETA FUNALTREXAMINE; ENADOLINE; FENTANYL; KAPPA OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NORBINALTORPHIMINE; OXYMORPHONE; SPIRADOLINE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; PYRROLIDINE DERIVATIVE;

ABDOMINAL DISTENSION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; COLORECTAL DISEASE; COLORECTAL DISTENSION ASSAY; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG CROSS REACTIVITY; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; VISCERAL PAIN; ANIMAL; COLON; DRUG EFFECT; DRUG POTENTIATION; RECTUM; SPRAGUE DAWLEY RAT;

RATTUS;

ANIMALS; COLON; FENTANYL; MALE; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; RECTUM;

EID: 59649101316     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.12.023     Document Type: Article

References (54)

1. Allerton C.A., Smith J.A., Hunter J.C., Hill R.G., and Hughes J. Correlation of ontogeny with function of [3H] U69593-labelled kappa opioid binding sites in the rat spinal cord. Brain Res 502 (1989) 149-157
2. Atweh S.F., and Kuhar M.J. Autoradiographic localization of opiate receptors in rat brain. I. Spinal cord and lower medulla. Brain Res 124 (1997) 53-67
3. Bie B., and Pan Z.Z. Presynaptic mechanisms for the anti-analgesic and anti-hyperalgesic actions of kappa-opioid receptors. J Neurosci 32 (2003) 7262-7268
4. Black D., and Trevethick M. The kappa opioid receptor is associated with perception of visceral pain. Gut 43 (1998) 312-313
5. Bonica J.J. Anatomical and physiological basis of nociception and pain. In: Bonica J.J. (Ed). The management of pain (1990), Lea & Fibiger, Philadelphia 28-94
6. Briggs, S.L., Interactions of mu and kappa opioid agonists. Ph.D. Thesis Dissertation. Mich. State Univ.: East Lansing, MI; 1996.
7. Briggs S.L., Rech R.H., and Sawyer D.C. Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats. Pharmacol Biochem Behav 60 (1998) 467-472
8. Briggs S.L., Sneed K., and Sawyer D.C. Antinociceptive effects of oxymophone-butorphanol-acepromazine combination in cats. Vet Surg 27 (1998) 466-472
9. Christianson J.A., and Gerhart G.F. Assessment of colon sensitivity by luminal distension in mice. Nat Protoc 2 (2007) 2624-2631
10. Coop A., and MacKerell A.D. The future of opioid analgesics. Amer J Pharm Educ 24 (2002) 198-205
11. Fundytus M.E. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 15 (2001) 29-58
12. Gebhart G.F. Modulation of cutaneous and visceral pain. In: Short C.P., and Van Poznak A. (Eds). Animal pain (1992), Churchill-Livingstone, New York 81-93
13. In: Hardman J.G., Gilman A.G., and Limbird L.E. (Eds). Goodman and Gilman's the pharmacological basis of therapeutics (1996), McGraw-Hill, New York 524-535
14. Harris L.S., and Pierson A.K. Some narcotic antagonists in the benzomorphan series. J Pharmacol Exp Ther 143 (1964) 141-148
15. He L., and Lee N.M. DynorphinA-(2-17) restores spinal/supraspinal morphine synergy in morphine-tolerant mice. J Pharmacol Exp Ther 280 (1997) 1210-1214
16. Herra'ez-Baranda L.A., Carretero J., Goza'lez-Sermiento R., Loarden M.L., Milane's M.V., and Rodriguez R.E. Evidence of involvement of the nNOS and the kappa-opioid receptor in the same intracellular network of the rat periaqueductal gray that controls morphine tolerance and dependence. Brain Res 137 (2005) 166-173
17. Houghton K.J., Rech R.H., Sawyer D.C., Durham R.A., Adams T., Langham M.A., et al. Dose-response of intravenous butorphanol to increase visceral nociceptive threshold in dogs. Proc Soc Exp Biol Med 197 (1991) 290-296
18. Janig W., and Morrison J.F.B. In: Cervero F., and Morrison J.F.B. (Eds). Functional properties of spinal visceral afferents supplying abdominal and pelvic organs with special emphasis on visceral nociception. Visceral sensation, progress in brain research vol. 67 (1986), Elsevier, New York 87-114
19. Jang S., Kim H., Kim D., Jeong M.W., Ma T., Kim S., et al. Attenuation of morphine tolerance and withdrawal syndrome by coadministration of nalbuphine. Arch Pharm Res 29 (2006) 677-684
20. Jones D.N., and Holtzman S.G. Long-term kappa-opioid receptor blockade following nor-binaltorphimine. Eur J Pharmacol 215 (1998) 345-348
21. Joshi S.K., and Gebhart G.F. Visceral pain. Curr Rev Pain 4 (2000) 499-506
22. Khotib J., Narita M., Suzuki M., Yajima Y., and Suzuki T. Functional interaction between opioid receptor types: up-regulation of mu- and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptors. Neuropharmacology 46 (2004) 531-540
23. Larsson M., Arvidsson S., Ekman C., and Bayati A. A model for chronic quantitative studies of colorectal sensitivity using balloon distension in conscious mice - effects of opioid receptor agonists. Neurogastroenterol Motil 15 (2003) 371-381
24. Margolis E.B., Hjelstad G.O., Bonci A., and Fields H.L. Both kappa and mu opioid agonists inhibit glutamate input to ventral segmental area neurons. J Neurophysiol 93 (2005) 3086-3093
25. Miaskowski C., Taiwo Y.O., and Levine J.D. Antinociception produced by selective opioids. Modulation of supraspinal antinociceptive effects by spinal opioids. Brain Res 608 (1993) 87-94
26. Narita M., Kishimoto Y., Ise Y., Yajima Y., Misawa K., and Suzuki T. Direct evidence of the mesolimbic kappa-opioid system in the morphine-induced rewarding effect under an inflammatory pain-like state. Neuropsychopharmacology 30 (2005) 111-118
27. Negus S.S., Schrode K., and Stevenson G.W. Mu/kappa opioid interactions in rhesus monkeys: implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16 (2008) 386-399
28. Nemmani K.V., and Mogil J.S. Serotonin-GABA interactions in the modulation of mu- and kappa-opioid analgesia. Neuropharmacology 44 (2003) 304-310
29. Ness T.J., and Gebhart G.F. Visceral pain: a review of experimental studies. Pain 41 (1990) 167-234
30. Pasternak G.W., and Wood P.L. Multiple mu receptors. Life Sci (1986) 1889-1898
31. Pearl S.M., and Glick S.D. Prolonged antagonism of morphine-induced locomotor stimulation by kappa-opioid agonists. Neurosci Lett 213 (1996) 5-8
32. Preston K.L., and Bigelow G.E. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther 264 (1993) 813-823
33. Ren M.F., Lu C.H., and Han J.S. Dynorphin-A-(1-13) antagonizes morphine analgesia in the spinal cord. Peptides 6 (1985) 1015-1020
34. Ross F.B., Wallis S.C., and Smith M.T. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side effects in rats. Pain 84 (2000) 421-428
35. Sawyer D.C., and Rech R.H. Analgesia and behavioral effects of butorphanol, nalbuphine, and pentazocine in the cat. J Amer Hosp Assoc 23 (1987) 438-446
36. Sawyer D.C., Rech R.H., and Durham R.A. Effects of ketamine and combination with acetylpromazine, diazepam, or butorphanol on visceral nociception in the cat. In: Domino E.F. (Ed). Status of ketamine in anesthesiology (1990), NPP Books, Ann Arbor, MI 247-259
37. Sawyer D.C., Rech R.H., Durham R.A., Adams T., Richter M.A., and Striler E.L. Dose-response to butorphanol administered subcutaneously to increase visceral nociceptive threshold in dogs. Amer Vet Res J 52 (1991) 1826-1830
38. Schmauss C., and Herz A. Intrathecally administered dynorphin (1-17) modulates morphine-induced antinociception differently in morphine-naïve and morphine-tolerant rats. Eur J Pharmacol. 135 (1987) 429-431
39. Schmauss C., and Yaksh T.L. In vivo studies of spinal opiate receptor systems mediating antinociception. II. Pharmacological profiles suggesting a differential association of mu, delta, and kappa receptors with visceral chemical and cutaneous thermal stimuli in the rat. J Pharmacol Exp Ther 228 (1984) 1-12
40. Smith H.S. Combination opioid analgesics. Pain Physician 11 (2008) 201-214
41. Song S.H., and Takemori A.E. Modulation of acute morphine tolerance by corticotropin-releasing factor and dynorphin A in mouse spinal cord. Life Sci 51 (1992) 107-111
42. Staahl C., Christrup L.L., Anderson S.D., Arendt-Nielsen L., and Drewes A.M. A comparative study of oxycodone and morphine in a multimodal, tissue-differentiated experimental pain model. Pain 123 (2006) 28-36
43. Stachura Z., and Herman Z.S. The influence of the kappa agonist spiradoline (U69593E) on the analgesic activity of some opioids at the spinal level. Pol J Pharmacol 45 (1994) 37-41
44. Steel R.G.D., and Torrie J.H. Principles and procedures of statistics, a biometrical approach (1984), McGraw-Hill, New York 41-59
45. Sutters K.A., Miaskowski C., Taiwo Y.O., and Levine J.D. Analgesic synergy and improved motor function produced by combinations of mu-delta and mu-kappa opioids. Brain Res 530 (1990) 290-294
46. Tao P.L., Hwang C.L., and Chen C.Y. U-50,488 blocks the development of morphine tolerance and dependence at a very low dose in guinea pigs. Eur J Pharmacol 256 3 (1994) 281-286
47. Verborgh C.M., Camu F., and Meert T.F. Interaction between sufentanil and U50, 488H with respect to antinociception and respiratory depression in rats. Acta Anaesthesiol Scand 41 (1997) 895-902
48. von Voigtlander P.F., and Lewis R.A. Analgesic and mechanistic evaluation of spiradoline, a potent kappa opioid. J Pharmacol Exp Ther 246 (1988) 259-262
49. Ward S.L., Portoghese P.S., and Takamori A.E. Pharmacological characterization in vivo of the novel opioid B-funaltrexamine. J Pharmacol Exp Ther 220 (1982) 494-498
50. Walker D.J., Zacny J.P., Galva K.E., and Lichtor J.L. Subjective, psychomotor, and physiological effects of cumulative doses of mixed-action opioids in healthy human volunteers. Psychopharmacology (Berl) 155 (2001) 362-371
51. Werz M.A., Grega D.S., and MacDonald R.L. Actions of mu, delta, and kappa opioid agonists on mouse primary afferent neurons in culture. J Pharmacol Exp Ther 243 (1987) 258-263
52. Willis W.D., and Westlund K.N. Neuroanatomy of the pain system and the pathways that modulate pain. J Clin Neurophysiol 14 (1997) 2-31
53. Yaksh T.L. Pharmacology of mechanisms of opioid analgesic activity. Acta Anaesthesiol Scand 41 (1997) 94-111
54. Yamamoto T., Ohno M., and Ueki S. A selective kappa opioid agonist, U-50, 488H, blocks the development of tolerance to morphine analgesia in rats. Eur J Pharmacol 156 (1988) 173-176